Earnings8-K
Results of Operations and Financial Condition
Show detailsHide details
2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 8.01 Other Events · 9.01 Financial Statements and Exhibits
PEPG
Pepgen Inc.
A clinical-stage biotech working to treat severe neuromuscular diseases, PepGen builds "oligonucleotide" medicines designed to fix faulty genetic instructions, using its EDO platform of cell-penetrating peptides to ferry drugs into muscle and other hard-to-reach tissues. Its lead candidate, PGN-EDODM1, targets myotonic dystrophy type 1 and has earned Orphan Drug and Fast Track designations. Founded in 2018, the company's name combines "Pep" for its peptide delivery technology and "Gen" for the genetic diseases it tackles.
CUSIP: 713317105HealthcareUS1 holder